StockData

Seres Therapeutics vs Upstream Bio

MCRB and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MCRB and UPB compare

Upstream Bio is the larger company, worth 8.4 times as much as Seres Therapeutics ($118M against $14.0M).

Seres Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1193% compared with −5712% at Upstream Bio.

Upstream Bio scores higher on the StockData Score (7 against 6 for Seres Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMCRBUPB
Size and price
Market cap$14.0M$118M
Share price$1.41$2.15
Change, 1 year−91.6%−90.8%
Change, 5 years−99.2%–
Beta (5Y)0.282.68
Employees6675
StockData Score
Total score67 (better)
Valuation score11
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S7.4× (better)41.0×
P/B0.4× (better)0.5×
FCF yield−366%–
Growth
Revenue growth (TTM)–2.5%
Revenue growth, 5Y average−52.7%–
Net income growth (TTM)−126%–
EPS growth (TTM)−121%–
Profitability
Operating margin−4463% (better)−6116%
Net margin−1193% (better)−5712%
FCF margin−2724%–
Return on equity−66.6%−53.5% (better)
Return on invested capital–−846%
Financial health
Debt / equity0.000.00
Current ratio2.1120.45 (better)
Altman Z-score−15.932.08 (better)
Piotroski F-score6 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.9%92.3%
Held by insiders2.3%8.6%
Insider net buying, 12 months−$10.0K (better)−$105K
Short interest, % of float3.5%7.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.